SPDR S&P Biotech ETF $XBI Position Raised by United Capital Management of KS Inc.

United Capital Management of KS Inc. grew its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 188,529 shares of the exchange traded fund’s stock after purchasing an additional 4,182 shares during the period. SPDR S&P Biotech ETF makes up about 2.6% of United Capital Management of KS Inc.’s portfolio, making the stock its 8th biggest position. United Capital Management of KS Inc.’s holdings in SPDR S&P Biotech ETF were worth $18,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in SPDR S&P Biotech ETF by 27.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after buying an additional 2,900,633 shares during the period. Bessemer Group Inc. boosted its stake in SPDR S&P Biotech ETF by 9.3% during the third quarter. Bessemer Group Inc. now owns 1,632,988 shares of the exchange traded fund’s stock worth $163,624,000 after buying an additional 138,322 shares during the period. Ameriprise Financial Inc. increased its position in SPDR S&P Biotech ETF by 123.0% during the second quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock valued at $72,542,000 after acquiring an additional 481,408 shares during the last quarter. Meitav Investment House Ltd. increased its position in SPDR S&P Biotech ETF by 70.3% during the third quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock valued at $68,156,000 after acquiring an additional 281,602 shares during the last quarter. Finally, Greenhouse Funds LLLP raised its stake in shares of SPDR S&P Biotech ETF by 17.3% in the second quarter. Greenhouse Funds LLLP now owns 579,667 shares of the exchange traded fund’s stock valued at $48,072,000 after acquiring an additional 85,422 shares during the period.

SPDR S&P Biotech ETF Trading Down 2.0%

SPDR S&P Biotech ETF stock opened at $123.90 on Friday. SPDR S&P Biotech ETF has a 12-month low of $66.66 and a 12-month high of $132.09. The firm has a 50-day moving average price of $125.19 and a 200-day moving average price of $113.54. The firm has a market capitalization of $8.28 billion, a PE ratio of 11.47 and a beta of 0.93.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.